While we appreciate and applaud the @linakhanFTC @FTC statement today that reminds health apps they are subject to the @FTC Breach Notification Rule (https://t.co/t3QXbW7gK2), it's important to note we have already gone MUCH farther to protect health data outside of HIPAA. 🧵
Seems like #aducanumab is “fake it til you make it” in drug dev. On the one hand, it seems like a long shot that this will help patients today measurably. On the other hand, does it help Alzheimer’s research cross a chasm out of limited public r&d funds? https://t.co/gnrmn6OyPt
How robust will ur favorite AI application be if ICD coding shifts, if reimbursement patterns change care, if response to a dangerous virus changes, or new drug introduced? Just a few examples of data set shifts that doctors muddle through daily that systematically upend ML apps.
The Physician Fee Schedule proposed rule is out❗️
A key change: public health measures in Promoting Interoperability
CMS proposes making electronic case reporting & immunization information system use required (both have been critical in COVID response) https://t.co/NLELvSno80
Inflation as measured by CPI increased at a 5.4% rate year-over-year last month and 0.9% month-over-month. Core inflation—without food/energy—rose 4.5% year-over-year and 0.9% month-over-month. A large part of the increase is due to cars and pandemic-affected services. 1/
@dp_oneill Good points. My hypothesis would be that though death is a relatively infrequent cause of attrition it drives the MLR down subsequently owing to high cost of end of life care. Survival bias I think would overwhelm the marginal cost associated with the entire cohort aging 1 year.
Am I the only one uncertain about interpreting an MLR for a cohort without describing the methodology for handling right censoring? Deaths lead to a more healthy remaining cohort over time. (One Medical S4 for Iora) https://t.co/0V6Z3h4Bga)
Still a little unclear what’s under the hood here, but seems as though if this were nothing more than an “easy button” for new players participating in Carequality framework-based data exchange, well, I think that would be a great addition to the marketplace.
@GauravSingalMD Before concluding that, may want to apply some adjustment for feedback received on platform that is popularized on timeliness (ie twitter). I think fair to describe RW feedback has been more mixed for certain results enriched for “could be cancer” (eg mammo).